A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection

Trial Profile

A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs NVR 3778 (Primary) ; Antivirals
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Novira Therapeutics
  • Most Recent Events

    • 15 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 17 Dec 2015 Planned end date changed from 1 Jan 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
    • 17 Dec 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top